Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ETX2514SUL versus colistin for severe Acinetobacter baumannii-calcoaceticus complex infections
MOH_2019-06-18_006079Phase 3Not yet recruiting
- Sponsor
- Entasis Therapeutics
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sulbactam + durlobactam in Acinetobacter baumannii-calcoaceticus complex infection, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and 4 more (3 arms), sponsored by Entasis Therapeutics. Primary endpoints: Efficacy comparison in Part A and Nephrotoxicity incidence in Part A. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
sulbactam + durlobactam
03
Conditions
Acinetobacter baumannii-calcoaceticus complex infectionhospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Bacteremiacomplicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on MOH_2019-06-18_006079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-18_006079.